<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211004052670N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-11-13</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Effectiveness of adding melatonin and sleep hygiene education to the usual treatment of attention deficit hyperactivity disorder with sleep phase delay syndrome.</public_title>
      <acronym>ADHD</acronym>
      <scientific_title>A comparative study of the effectiveness of adding melatonin and sleep hygiene education to the usual treatment (pharmacological and non-pharmacological treatment) in reducing the symptoms of attention deficit hyperactivity disorder in adolescents with attention deficit hyperactivity disorder and sleep phase delay syndrome.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>75</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71928</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The sample in this research consists of 75 adolescents with ADHD and sleep phase delay syndrome with the opinion of a specialist in pediatric psychiatry based on the fifth edition of the Diagnostic and Statistical Manual of Psychiatric Disorders, who are selected by available sampling. Then on 25 leaves letter A, 25 leaves letter B, and 25 leaves letter C are written and each is placed in an envelope. Then each patient is asked to choose one envelope from among the envelopes. According to the selected envelope, the patient will be allocated to one of the three groups. The size of each group is 25 people and the waiting list is also 25 people.</study_design>
      <phase>3</phase>
      <hc_freetext>Attention Deficit-Hyperactivity Disorder.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: For each patient, 3 mg of melatonin is added to his routine treatment. The chemical structure of this drug is similar to serotonin. It has a fast and complete oral absorption and reaches the plasma peak within an hour, so it is used for people with sleep delay problems. In this group, patients are first given a checklist of drug side effects, and the checklist is checked during three visits. This group is treated with melatonin for 5 weeks. Intervention 2: Intervention group 2: This educational program as a psychoeducational program includes 5 50-minute sessions that are conducted by a psychologist for parents of teenagers in a group and during 5 consecutive days. The first session: In this session, how teenagers are deprived of enough sleep to Parents are explained. The second session: why teenagers are so affected by lack of sleep. In other words, the causes and factors of sleep deprivation are taught to parents in this section. The third session: The consequences of sleep deprivation in teenagers are taught to parents. The fourth and fifth sessions: How can you help teenagers get enough sleep. In these two sessions, parents are taught various effective methods to help teenagers improve their sleep quality and quantity.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Its Release Schedule Is Not Yet Known</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Afsaneh Karbasi Amel</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 15, 2nd Floor, Kaj Blind Alley, Mehrdad Alley 3, 2nd Apadana Street</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8166795471</zip>
        <telephone>+98 31 3641 1255</telephone>
        <email>afsaneh_karbasi@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Afsaneh Karbasi amel</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.15- KAJ Ave -MEHRDAD Street-APADANA DOVOM Blvd-</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8166795471</zip>
        <telephone>+98 31 3641 1255</telephone>
        <email>afsaneh_karbasi@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Definitive diagnosis of ADHD with DSPS between 12 and 18 years
Informed consent to participate in the research project
Having minimum education (reading and writing literacy) of parents for sleep training for teenagers</inclusion_criteria>
      <agemin>12 years</agemin>
      <agemax>18 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Suffering from chronic physical diseases including diabetes, liver problems, immune system defects and autoimmune diseases
Taking medicine with side effects of sleep problems such as insomnia or hypersomnia</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F90.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Attention-deficit hyperactivity disorder, combined type</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: For each patient, 3 mg of melatonin is added to his routine treatment. The chemical structure of this drug is similar to serotonin. It has a fast and complete oral absorption and reaches the plasma peak within an hour, so it is used for people with sleep delay problems. In this group, patients are first given a checklist of drug side effects, and the checklist is checked during three visits. This group is treated with melatonin for 5 weeks.</i_keyword>
      <i_keyword>Intervention group 2: This educational program as a psychoeducational program includes 5 50-minute sessions that are conducted by a psychologist for parents of teenagers in a group and during 5 consecutive days. The first session: In this session, how teenagers are deprived of enough sleep to Parents are explained. The second session: why teenagers are so affected by lack of sleep. In other words, the causes and factors of sleep deprivation are taught to parents in this section. The third session: The consequences of sleep deprivation in teenagers are taught to parents. The fourth and fifth sessions: How can you help teenagers get enough sleep. In these two sessions, parents are taught various effective methods to help teenagers improve their sleep quality and quantity.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Determining the mean scores of Conners Hyperactivity Questionnaire. Timepoint: The questionnaire is administered at the baseline visit (before the intervention), after participating in sleep health education sessions and taking melatonin medicine, and then three months after the intervention is completed for follow-up. Method of measurement: Conners Hyperactivity Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Sleep quality score. Timepoint: The questionnaire is administered at the baseline visit (before the intervention), after the training sessions on sleep hygiene and the use of melatonin medication, and three months after the end of the intervention for follow-up. Method of measurement: Petersburg Sleep Quality Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-07-12</approval_date>
        <contact_name>Ethical Committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Ibn Sina Street, Amin Hospital Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
